Analysts expect Medpace Holdings, Inc. (NASDAQ:MEDP) to post earnings per share of $1.01 for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Medpace’s earnings. The highest EPS estimate is $1.03 and the lowest is $0.98. Medpace reported earnings of $0.80 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 26.3%. The firm is scheduled to issue its next earnings report after the market closes on Monday, April 26th.
According to Zacks, analysts expect that Medpace will report full year earnings of $4.35 per share for the current year, with EPS estimates ranging from $4.30 to $4.38. For the next year, analysts anticipate that the company will post earnings of $5.04 per share, with EPS estimates ranging from $4.95 to $5.09. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Medpace.
Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Sunday, February 14th. The company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.11. The business had revenue of $259.68 million for the quarter, compared to analyst estimates of $246.41 million. Medpace had a return on equity of 17.67% and a net margin of 13.87%.
In other Medpace news, major shareholder Medpace Investors, Llc sold 26,666 shares of the company’s stock in a transaction that occurred on Friday, January 8th. The stock was sold at an average price of $140.71, for a total value of $3,752,172.86. Following the transaction, the insider now directly owns 6,457,202 shares of the company’s stock, valued at approximately $908,592,893.42. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Jesse J. Geiger sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 10th. The shares were sold at an average price of $160.00, for a total value of $640,000.00. Following the completion of the transaction, the chief financial officer now directly owns 10,382 shares in the company, valued at $1,661,120. The disclosure for this sale can be found here. Insiders have sold a total of 40,666 shares of company stock worth $5,946,973 over the last three months. 26.00% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the business. DekaBank Deutsche Girozentrale raised its position in shares of Medpace by 108.4% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 14,900 shares of the company’s stock valued at $2,035,000 after purchasing an additional 7,750 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Medpace in the 4th quarter valued at approximately $2,346,000. Norges Bank bought a new stake in shares of Medpace in the 4th quarter valued at approximately $46,440,000. Hsbc Holdings PLC increased its holdings in shares of Medpace by 47.9% in the 4th quarter. Hsbc Holdings PLC now owns 4,212 shares of the company’s stock valued at $585,000 after acquiring an additional 1,365 shares during the last quarter. Finally, Truist Financial Corp increased its holdings in shares of Medpace by 34.0% in the 4th quarter. Truist Financial Corp now owns 9,346 shares of the company’s stock valued at $1,300,000 after acquiring an additional 2,371 shares during the last quarter. 74.44% of the stock is currently owned by institutional investors.
Shares of NASDAQ MEDP traded up $3.24 during midday trading on Friday, hitting $170.64. The stock had a trading volume of 847 shares, compared to its average volume of 203,247. The company has a market capitalization of $6.14 billion, a price-to-earnings ratio of 51.19 and a beta of 1.35. Medpace has a 1-year low of $73.62 and a 1-year high of $177.12. The company has a fifty day moving average price of $162.49 and a 200 day moving average price of $138.60.
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Featured Story: What is a conference call?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.